BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11194952)

  • 1. [Positron emission tomography in thoracic radiography].
    Vaylet F; Foehrenbach H; Guigay J; de Dreuille O; Maszelin P; Grassin F; Margery J; Dot JM; Gaillard JF; L'Her P
    Cancer Radiother; 2000 Nov; 4 Suppl 1():13s-16s. PubMed ID: 11194952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interest in 18-FDG positron emission tomography in radiotherapy planning: example of lung cancer radiotherapy].
    Vaylet F; de Dreuille O; L'her P; Maszelin P; Guigay J; Foehrenbach H; Grassin F; Margery J; Gaillard JF
    Cancer Radiother; 2001 Oct; 5(5):685-90. PubMed ID: 11715319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Positron emission tomography for detection of lymph node metastases in lung cancer].
    Sugio K; Sasaki M; Yamazaki K; Kase S; Sugimachi K
    Nihon Geka Gakkai Zasshi; 1999 Nov; 100(11):718-23. PubMed ID: 10629837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
    Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
    Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new look at breast cancer.
    Wagner HN
    J Nucl Med; 1999 Jun; 40(6):1009-10. PubMed ID: 10452319
    [No Abstract]   [Full Text] [Related]  

  • 8. [Combined functional and morphological imaging with PET/CT systems].
    Kaim AH; von Schulthess GK
    Praxis (Bern 1994); 2003 Feb; 92(6):225-7. PubMed ID: 12645384
    [No Abstract]   [Full Text] [Related]  

  • 9. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
    Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
    Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) in ORL and pulmonary oncology].
    Barghouth G; Allaoua M; Goerres GW
    Rev Med Suisse Romande; 2000 Jun; 120(6):535-42. PubMed ID: 11014099
    [No Abstract]   [Full Text] [Related]  

  • 11. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET.
    Hara T; Inagaki K; Kosaka N; Morita T
    J Nucl Med; 2000 Sep; 41(9):1507-13. PubMed ID: 10994730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18)F-fluorodeoxyglucose positron emission tomography: false-positive lung scan.
    Khandani AH; Keller SM; Blaufox MD
    Semin Nucl Med; 2002 Jul; 32(3):212-3. PubMed ID: 12105801
    [No Abstract]   [Full Text] [Related]  

  • 13. FDG positron emission tomography in the diagnosis of peripheral pulmonary focal lesions.
    Halter G; Storck M; Guhlmann A; Frank J; Grosse S; Liewald F
    Thorac Cardiovasc Surg; 2000 Apr; 48(2):97-101. PubMed ID: 11028711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
    Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
    J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Problems of differential diagnosis in the diagnosis of mediastinal and pulmonary metastases with F-a8-FDG PET].
    Adams S; Nickel E; Hör G
    Nuklearmedizin; 2000 Aug; 39(5):N83-4. PubMed ID: 10984898
    [No Abstract]   [Full Text] [Related]  

  • 16. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
    Graeber GM; Gupta NC; Murray GF
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner.
    Shreve PD; Steventon RS; Deters EC; Kison PV; Gross MD; Wahl RL
    Radiology; 1998 May; 207(2):431-7. PubMed ID: 9577492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET)].
    Di Martino E; Nowak B; Krombach GA; Sellhaus B; Hausmann R; Cremerius U; Büll U; Westhofen M
    Laryngorhinootologie; 2000 Apr; 79(4):201-6. PubMed ID: 10838683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
    Lardinois D; Weder W; Hany TF; Kamel EM; Korom S; Seifert B; von Schulthess GK; Steinert HC
    N Engl J Med; 2003 Jun; 348(25):2500-7. PubMed ID: 12815135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Silicosis callosities or bronchial carcinoma: on the problem of functional differentiation using FDG-PET].
    Zell L; Hellwig D; Sommerfeld A; Ukena D; Buchter A; Kirsch CM
    Nuklearmedizin; 2000; 39(3):N35-8. PubMed ID: 10834198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.